IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome
IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, and PsychoGenics Inc., a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that the companies have entered into an additional services agreement to identify the efficacy of novel drug candidates in preclinical animal models of Dravet syndrome.
Under the terms of this second agreement, PsychoGenics will evaluate the anti-seizure efficacy of first-in-class selective-NKCC1 inhibitors, which aim to reduce intracellular chloride concentration and restore the physiological hyperpolarizing and inhibitory GABAergic transmission in a preclinical model of Dravet syndrome.
"Our internal research efforts give us confidence that modulating intracellular chloride could be an effective treatment for reducing seizures in individuals affected by Dravet syndrome," said Andrea P. Malizia, Ph.D., MBA, Chief Executive Officer at IAMA Therapeutics. "The expertise of PsychoGenics in anti-epilepsy drug testing through the electrographic and behavioral identification of seizures will allow us to accelerate the efforts toward the development of a potential treatment."
"We are excited to be working with IAMA Therapeutics," said Stephen Morairty, Ph.D., Vice President of Translational Neuroscience at PsychoGenics. "Dravet syndrome is a severe disorder lacking adequate therapies. We will use our extensiv knowledge of the seizure phenotype in a preclinic model of Dravet syndrome to carefully evaluate the efficacy of these first-in-class selective-NKCC1 inhibitors."
About Dravet syndrome
About IAMA Therapeutics
For more information, please visit https://iamatherapeutics.com/.
About PsychoGenics Inc.
For more information on PsychoGenics Inc., visit www.psychogenics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005859/en/